Back to Search
Start Over
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
- Source :
- The Lancet; February 2016, Vol. 387 Issue: 10020 p770-778, 9p
- Publication Year :
- 2016
-
Abstract
- Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis. Both ibrutinib and temsirolimus have shown single-agent activity in patients with relapsed or refractory mantle-cell lymphoma. We undertook a phase 3 study to assess the efficacy and safety of ibrutinib versus temsirolimus in relapsed or refractory mantle-cell lymphoma.
Details
- Language :
- English
- ISSN :
- 01406736 and 1474547X
- Volume :
- 387
- Issue :
- 10020
- Database :
- Supplemental Index
- Journal :
- The Lancet
- Publication Type :
- Periodical
- Accession number :
- ejs38103018
- Full Text :
- https://doi.org/10.1016/S0140-6736(15)00667-4